CONCLUSIONS Despite a similar LVEF, lower baseline LV-GLS is associated with early improvement in LVEF following TAVR, suggesting the existence of undetectable LV functional differences by conventional echocardiographic parameters. Detailed LV assessment with strain echocardiography as well as conventional echocardiography may help predict the LV functional recovery after TAVR. 12 Quebec Heart and Lung Institute, Laval University, Quebec, QC BACKGROUND The release of cardiac biomarkers of myocardial injury after transcatheter aortic valve replacement (TAVR) is common, but no data exist on those patients undergoing TAVR through transaortic approach. We aimed to evaluate the incidence and prognostic significance of the increase in cardiac biomarkers in non-transfemoral TAVR candidates, comparing transaortic and transapical approaches.
BACKGROUND The release of cardiac biomarkers of myocardial injury after transcatheter aortic valve replacement (TAVR) is common, but no data exist on those patients undergoing TAVR through transaortic approach. We aimed to evaluate the incidence and prognostic significance of the increase in cardiac biomarkers in non-transfemoral TAVR candidates, comparing transaortic and transapical approaches.
METHODS After excluding patients deemed unsuitable for transfemoral TAVR, 251 consecutive patients (transaortic¼45; transapical¼206) were prospectively evaluated. Creatine kinase-MB (CK-MB) and cardiac troponin T (cTnT) levels were measured at baseline and at 6-12,24,48, and 72 hours following TAVR. Baseline and 6-12 month echocardiographic and clinical follow-up were performed. Patients were analyzed overall and also matched using a propensity score matching (1:2).
RESULTS Following TAVR, cTnT increased above the upper normal values in all patients (peak value: 0.64mg/l[IQR: 0.39-1.03mg/l]), whereas CK-MB levels increased in 88% of patients (transaortic:51%, transapical:96%, p<0.001; ). Compared with the transaortic approach, transapical approach was associated with a greater rise in both cardiac biomarkers (p<0.001 for both), and a lesser improvement in left ventricular ejection (p¼0.058) and global longitudinal strain (p¼0.039) at 6-12-month follow-up. These results were also consistent for the propensity matched score analysis (transaortic¼37; transapical¼65). Importantly, greater increases of cTnT levels independently associated with 30-day and 1-year overall and cardiovascular mortality (p<0.001 for all). A 15-fold rise in cTnT levels was the optimal threshold for determining poorer outcomes (p<0.001).
CONCLUSIONS Peri-procedural TAVR-related myocardial injury in non-transfemoral candidates was demonstrated in all patients, but transapical approach was associated with significantly greater myocardial injury compared with transaortic approach. A higher degree of myocardial injury translated into reduced left ventricular function improvement and lower early-and mid-term survival rates. 29 Quebec Heart and Lung Institute, Quebec, Canada BACKGROUND Cardiac biomarker release signifying myocardial injury after transcatheter aortic valve replacement (TAVR) is common, yet its clinical impact within a large TAVR population receiving differing types of valve and procedural approaches is unknown. This precluded a validation of the most appropriate biochemical threshold for defining clinically relevant myocardial infarction post-TAVR. The objectives were to determine, in a large cohort of patients undergoing TAVR, the incidence, clinical impact and factors associated with cardiac biomarker elevation post-TAVR.
METHODS This multicenter study included 1,131 consecutive patients undergoing TAVR with balloon-(58%) or self-expandable (42%) valves. Transfemoral, transapical (TA), transaortic and trans-subclavian approaches were selected in 73.1%, 20.3%, 4.2% and 2.3% of the patients, respectively. Creatine kinase-MB (CK-MB) measurements were obtained at baseline and at several time points within the initial 72 hours post-TAVR. Echocardiography was performed at baseline and at 6-to 12-month follow-up.
RESULTS Overall, 66% of the TAVR population demonstrated some degree of myocardial injury as determined by a rise in CK-MB levels [peak value (IQR): 1.6-fold (0.9 to 2.8-fold)]. TA approach was independently associated with higher peak of CK-MB levels (p <0.001), and this translated into impaired systolic left ventricular function at 6-12 months post-TAVR (p <0.01). A greater rise in CK-MB levels independently associated with an increased 30-day, late (median of 21 [8-36]months) overall and cardiovascular mortality (p <0.001 for all). A >5-fold rise in CK-MB levels appeared to be the optimal threshold for associating with significantly worse clinical outcomes (p <0.001).
CONCLUSIONS Some degree of myocardial injury was detected in two-thirds of patients post-TAVR, especially in those undergoing TA-TAVR. A greater rise in CK-MB levels associated with increased acute and late mortality, imparting a negative impact on left ventricular function. A CK-MB rise >5-fold from baseline appears to be the optimal threshold for defining clinically relevant myocardial infarction post-TAVR. BACKGROUND To analyze our single center experience with transcatheter aortic valve implantation (TAVI) using the Direct Flow (DF) prosthesis and address specifically the impact of native AV calcification degree and distribution on prosthetic hemodynamic performance.
METHODS A consecutive series of patients with severe symptomatic aortic valve stenosis (AVS) were included in the present study. Data were prospectively collected and retrospectively analyzed. Patients were divided in 3 groups according to the amount of AV calcification as detected at preoperative cardiac CT ( group I <20%, group II between 20-50%, and group III over 50% of the total AV area). Perioperative and mid-term follow-up outcomes were compared.
RESULTS A total of 116 patients were evaluated. Group I included 46%, group II 46%, and group III the remaining 8% of the patients. Preoperative trans-AV gradient and calcification extension along the aortic unit were significantly higher in groups II and III (p¼0.008 and p<0.0001) and a trend for higher logistic euro-SCORE was present in group III (p¼0.08). Average CT perimeter derived annular diameter was similar in the 3 groups (24.7AE2.0; 24.9AE2.0; 24.8AE 1.3 mm; p¼0.8) and average implanted prosthesis size was also comparable (26.0AE1.5; 25.7AE1.5; 25.6AE1.4; p¼0.5). No patient required conversion to conventional surgery or emergent cardiopulmonary bypass support. A total of 13 patients (11%) had a mild paravalvular leak and the remaining patients had no or trivial regurgitation. Clinical outcomes and hemodynamic valve performance, including trans-prosthetic gradients, AV maximal velocity, and effective orifice area, were similar in the 3 groups at discharge and at the various stages of postoperative follow-up. Midterm follow-up predicted survival was 88.6% in group I, 96.8 % in group II, and 80.0% in group III (MantelCox p¼0.08).
CONCLUSIONS Independently by the AV calcification distribution, adequate valve sizing and implantation can be achieved with this inflatable non-metallic prosthesis. As shown in our experience, the DF prosthesis preserves a consistent and satisfactory hemodynamic profile even in patients with a higher native AV calcification burden. Moreover, a trend for higher follow-up predicted mortality should be expected in patients with higher AV calcification burden, most probably as a result of their more complex overall comorbid profile. CONCLUSIONS Our TAVI-FP had a high rate of adherence. Cardiac mortality still represented the predominant cause of death, occurring in more than 50% within the first year. The investment of every effort to include all TAVI patients in a centralized program may be valuable, since in-loco availability of expertise and techniques may impact on outcome. Finally, the high early mortality may raise the issue whether to anticipate at 30 days the first TAVI-FP visit in this frail and complex population.
